Ataxia is a neurological disorder characterized by impaired coordination of movement due to damage or dysfunction in the brain, most commonly the cerebellum.
It arises from various etiologies, including genetic conditions, autoimmune diseases, stroke, and chronic alcohol abuse.

There are three main types of ataxia, classified according to their location: cerebellar ataxia, sensory ataxia and vestibular ataxia.

The Regentime partially differentiated stem cell treatment promotes neuroregeneration, modulate neuroinflammation, and support the repair of damaged neural pathways. It also provides neuroprotection through several mechanisms, including the secretion of neurotrophic factors that stimulate neural cell proliferation and differentiation, modulation of the immune system to reduce ongoing neurodestructive processes, enhancement of vascular supply to the nervous system, and reduction of free radicals and reactive oxygen species that can damage neurons.

The Regentime procedure for Ataxia involves a 5-day stay in Lebanon, with prices ranging from 25,000 USD to 36,700USD.